According to the results announced at the 2018 ASCO annual meeting, the CDK4/6 inhibitors pabociclib (Ibrance) and cetuximab (Erbitux) combined treatment of platinum-resistant and HPV-independent recurrent/metastatic head and neck The overall response rate for patients with squamous cell carcinoma (HNSCC) is 39%. In a non-randomized, 3-arm, phase II trial (NCT02101034), the results of a group of studies have a median progression-free survival (PFS) of 5.4 months, a median overall survival (OS) of 9.5 months, and a 1-year OS The rate is 35%.
In this study, 30 patients with HNSCC unrelated to HPV progressed after platinum-based therapy for relapsed/metastatic disease and participated in the trial. Patients who had previously received cetuximab for relapse and HPV-related oropharyngeal cancer were not eligible. Patients received palbociclib from day 1 to day 21, 125 mg daily; cetuximab, with a starting dose of 400 mg/m 2 and then 250 mg/m 2 per week for a period of 28 days until the disease progressed or withdrew the study. The researchers performed imaging examinations before treatment and after every 2 cycles.
रोगियों की औसत आयु 67 वर्ष थी, और ट्यूमर स्थल मौखिक गुहा (47%), स्वरयंत्र (27%), और ऑरोफरीनक्स (13%) थे। 20% रोगियों में स्थानीय क्षेत्रीय मेटास्टेस हैं, 27% में दूर के मेटास्टेस हैं, और 53% में दोनों हैं। पंद्रह (50%) रोगियों को ≥ 2 उपचार प्राप्त हुए।
28 मूल्यांकन योग्य रोगियों में से 11 (39%) में ट्यूमर प्रतिक्रियाएं थीं, जिनमें 3 (11%) पूर्ण प्रतिक्रियाएं और 8 (29%) आंशिक प्रतिक्रियाएं थीं। चौदह (50%) रोगियों को स्थिर बीमारी थी, 3 (11%) रोगियों में प्रगति थी, और 70% में ट्यूमर के घाव कम हो गए थे।
Researcher Dr. Adkins said that Palbociclib and cetuximab have strong antitumor activity in platinum-resistant HPV-independent head and neck cancer, and biologically targeted therapy for HPV-independent head and neck cancer is an effective treatment strategy. . We look forward to the better results of the follow-up research.